Minerva Neurosciences Inc stock is traded at $2.56, with a volume of 95,698. It is up +2.81% in the last 24 hours and down -11.42% over the past month. Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
Previous Close:
$2.49
Open:
$2.55
24h Volume:
95,698
Relative Volume:
0.40
Market Cap:
$127.58M
Revenue:
-
Net Income/Loss:
-$293.42M
P/E Ratio:
-
EPS:
-$29.16
Net Cash Flow:
-$14.87M
1W Performance:
+11.30%
1M Performance:
-11.42%
6M Performance:
-54.29%
1Y Performance:
-36.00%
1-Day Range:
$2.46$2.58
1-Week Range:
$2.20$2.76
52-Week Range:
$1.96$8.80
Minerva Neurosciences Inc Stock (NERV) Company Profile
Name
Minerva Neurosciences IncSector
HealthcareIndustry
BiotechnologyPhone
617-600-7373Address
1500 DISTRICT AVENUE, BURLINGTON, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS